Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.
He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.
Imugene’s executive chairman Paul Hopper said: “Imugene continues to attract a world class team.
“We welcome Dr Eckstein to the board and look forward to working together to advance our highly promising cancer immuno therapy pipeline.”
Strong pipeline of cancer vaccines in development
The company has a strong pipeline of cancer vaccines in development.